Similar Efficacy, Safety, and Immune Improvement Through 96 Weeks in Individuals With Limited HIV-1 Treatment Options Using Twice-Daily Dolutegravir- or Fostemsavir-Based Regimens
Clicks: 3
ID: 324419
2026
Article Quality & Performance Metrics
Overall Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
0.0
/100
0 views
0 readers
AI Quality Assessment
Not analyzed
Abstract
Abstract Constructing suppressive regimens for individuals with multidrug-resistant HIV-1 can be challenging. Separate analyses of 96-week outcomes from the phase 3 VIKING-3 and BRIGHTE studies demonstrate that twice-daily dolutegravir-based and fostemsavir-based regimens each provide robust viral suppression, favorable safety profiles, and CD4+ T-cell count improvement in this population.
| Reference Key |
openalex_W7201998237
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Antonella Castagna, Iacopo Marcon, Fangfang Du, Bo Li, Marcia Wang, Andrew L. Clark, Cynthia Donovan, Bryn Jones, Manyu Prakash |
| Journal | Open forum infectious diseases |
| Year | 2026 |
| DOI |
10.1093/ofid/ofag487
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.